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INTRODUCTION
With the help of effective screening and treatment methods, 
mortality of cervical cancer has been greatly reduced. How­
ever, cervical cancer still is the second leading cause of cancer 
deaths in women worldwide [1]. The single most important 
factor in cervical oncogenesis is high oncogenic risk human 
pa  pillomaviruses (HPVs). HPVs interfere with Rb and p53 fun  c­
tion to make cervical epithelial cells cancer­prone state. How­
ever, only a small portion of HPV­infected patients de  velop 
cer  vical cancer and this necessitates further studies of other 
factors, including cancer­related genes at the molecular level. 
Among the genes studied so far, fibroblast growth factor re­
cep  tor (FGFR) is found constitutively activated [2]. Since the 
introduction of genome­wide, high­throughput research 
modalities, many studies to find disease­specific markers were 
conducted. As a result, they proposed several genes or gene 
products to have prognostic significance. Among the targets, 
significance of syndecans is reported in a few solid tumors 
and blood cancers. 
Syndecans are plasma membrane proteoglycans and their 
cytoplasmic domain is thought to interact with the actin cyto­
skeleton [3]. They act as co­receptors by binding fibroblast 
growth factors (FGFs) and presenting them to FGFRs [3]. There 
are 4 different kinds of syndecans in vertebrates [4]. Among 
syndecans, which are expressed in various types of cells, synde­
can­1 (SDC1) is expressed in epithelia and plasma cells [5].
Several studies on the relationship between syndecan ex­
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Objective: Syndecans are reported to have variable expression in several solid tumors and blood cancers. The cause provoking 
altered expression of syndecans is not known to date. We studied copy number status of syndecan­1 (SDC1) and significance of 
SDC1 gene product (syndecan­1, SDC1) expression in cervical cancers.
Methods: Using 121 cases of cervical cancer tissues, we screened SDC1 expression pattern using immunohistochemistry. 
We analyzed the relationship between SDC1 expression and clinicopathological parameters. To find possible causes of the 
expression change, we exploited interphase fluorescent in situ hybridization to screen copy number alteration of SDC1.
Results: Among 121 cases, 101 (83.5%) were positive and 20 (16.4%) were negative for SDC1. Among the parameters, age, 
histological type, and grade were significantly associated with SDC1 expression (p<0.05). Strong SDC1 expression in the 
cytoplasm showed better patient survival (p=0.02). In multivariate regression model, grade and SDC1 expression were 
independent prognostic factors (p<0.05). SDC1 in cervical cancers did not show copy number alteration.
Conclusion: Strong SDC1 expression in the cytoplasm of tumor cells predicts better patient survival. The change of SDC1 
expression in cervical cancers is not caused by copy number alteration of the gene.
Keywords: Carcinoma, squamous cell, DNA copy number variations, Gene expression, Syndecan­1, Uterine cervical neoplasms
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pre  ssion and cancers were conducted. SDC1 expressions in 
various tumors, including head and neck cancer [6], hepato­
cellular carcinoma [7], mesothelioma [8], and lung cancer [9], 
were decreased. However, in some malignant tumors, such as 
endometrial cancer [10], ovarian cancer [11] and pancreatic 
can  cer [12], SDC1 expression is increased. Those studies repor­
ted quantitative changes of SDC1 expression and the nature 
of the changes is dependent on the organ that the tumor has 
occurred. The syndecan family of matrix receptors is known 
to involve integrin (β4)­dependent signaling in human squa­
mous carcinoma cells [13]. 
Prognostic significance of SDC1 expression is evaluated in 
several human cancers. Gallbladder cancer with SDC1 ex  pre­
ssion showed more frequent lymph node metastasis [14]. 
In this study, we compared SDC1 expression with several pa­
tho  logic parameters in cervical cancers to find any significant 
association. To find possible cause of changes in SDC1 expre­
ssion, we measured copy numbers of SDC1 in cervical cancers 
using fluorescent in situ hybridization (FISH).
MATERIALS AND METHODS
1. Patients and tumor samples
This study included tumor tissues surgically resected from 
121 patients who visited Seoul St. Mary’s Hospital and were 
diagnosed with uterine cervical cancer between 1999 and 
2003. Patients’ age was between 28 and 77 (mean, 50) years 
old. Most of patients were in FIGO stage I (69 cases, 57.0%) 
and II (48 cases, 39.7%). Eighty­two cases (68%) of patients 
were treated with combination chemotherapy consisting 
of cis  platin and etoposide before operation. Tumor­specific 
sur    vival data (median, 61 months; range, 0.5 to 151 months) 
was available. The disease relapsed in 17 patients (14%), and 
20 patients (17%) died of the disease. Using the tissues, tis­
sue microarray (TMA) blocks were constructed and used for 
immunohistochemical staining and interphase FISH. Human 
tissue acquisition and its use followed the Institutional Review 
Board­approved protocol (CUMC10U917) at the Catholic Uni­
versity of Korea School of Medicine.
2. Immunohistochemistry
Sections from TMA blocks were transferred to ProbeOn Plus 
slides (Fisher Scientific, Pittsburgh, PA, USA) and incubated for two 
hours in 56
oC chamber (Agilent Technologies, Santa Clara, CA, 
USA). The sections were deparaffinized in xylene 3 times and 
re    hydrated through 100%, 90%, 80%, 70% ethanol and Tris­buff­
ered saline (TBS, pH 7.4). For antigen retrieval, the ti  ssues were 
im  mersed in 10 mM sodium citrate buffer (pH 6.0) and boiled 
in a microwave for 20 minutes. After treating the tissues with 
3% H2O2 in phosphate buffered saline (PBS), the tissues were 
incubated with diluted (1:50) mouse mono  clo  nal antibody 
to SDC1 (Abcam, Cambridge, UK) at 4
oC over  night. After in­
cu  bating the tissue with biotinylated anti­mouse antibody 
(Ab  nova, Walnut, CA, USA), TSA HRP System (PerkinElmer, 
Wal  tham, MA, USA) was used to amplify signal intensity. For 
vi  sualization, liquid DAB+substrate chromogen system (Dako, 
Glostrup, Denmark) was used. Immunoreactivity of SDC1 was 
classified according to the percentage of tu  mor cells showing 
cytoplasmic stain; strong, >50% of cells stained; weak, 10­50% 
of cells stained; negative, <10% of cells stained. Two patho  lo­
gi  sts analyzed the immunoreactivity in  dependently. 
3. Fluorescent FISH
To synthesize SDC1 FISH probe, we used BioPrime Array CGH 
Genomic Labeling Module (Invitrogen, Carlsbad, CA, USA). 
BAC clone (PRP11­202B22; Invitrogen) was used as template 
and Spectrum Orange­dUTP (Abbott Molecular, Abbott Park, IL, 
USA) was used to label the probe. Aquarius Satellite probe of 
chro  mo  some 2 (Cytocell, Cambridge, UK) was purchased as 
the reference probe. Location of homemade SDC1 probe was 
confirmed in metaphase spread of normal peripheral mo  no­
nuclear cells. Tissue processing and hybridization was done 
using Paraffin Pretreatment Kit I (Abbott Molecular) and Ther­
moBrite (Abbott Molecular). We followed the manu  facturer’
s recommended FISH protocols. We counted the num  ber of 
fluorescent spots in at least 100 nuclei in each case.
4. Statistical analysis
Chi­square test and Fisher­exact test was used to evaluate 
sig  ni  ficance of SDC1 expression in terms of pathologic fea­
tures. The numbers of target spots and reference spots in FISH 
were compared using the chi­square test. For survival analysis, 
Kaplan­Meier method was used. To test the difference be  tween 
survival curves of different groups, we used the non  pa  ra  me  t  ric 
log­rank  test.  We  used  Cox’s  multivariate  pro  portional  ha  zard 
model to determine the prognostic values of selected cli  ni­
co  pathologic parameters. We used R ver. 2.10 (R foundation, 
Vienna, Austria) for statistical cal  culations and pro  duction of 
graphs.
RESULTS
1. Relationship between SDC1 expression and pathologic 
parameters
Normal squamous epithelial cells showed membranous pa­
ttern of SDC1 expression. Cytoplasm of normal cervical epi­Syndecan-1 expression in cervical cancers
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the    lial cells did not show SDC1 expression. On the contrary, 
cyto  plasmic pattern of SDC1 expression was found in cancer 
cells in 101 cases (83.5%) of cervical cancers (Fig. 1). We com­
pared the status of cytoplasmic SDC1 expression and some 
patholo  gic parameters. SDC1 was more frequently expressed 
in squ  a  mous cell carcinomas than adenocarcinomas and 
adeno  squa  mous carcinomas (p=0.001). High grade tumors 
had less percentage of SDC1 expression than low grade tu­
mors (p=0.036). We could not find any correlation between 
status of recurrence, lymph node metastasis, tumor stage and 
SDC1 expression (Table 1). Multivariate analysis showed that 
tumor grade and strong SDC1 expression were independent 
prognostic factors for survival (Table 2).
2. Copy number status of SDC1
There was no significant difference between the numbers of 
target (SDC1) spots and references spots (p>0.05) in the cases 
showing increased SDC1 immunoreactivity (Fig. 2).
3. Survival analysis
We analyzed patient survival among the groups with differ­
ent SDC1 expression. Difference between the group of strong 
SDC1 expression and other groups was statistically significant 
(p=0.0219) (Fig. 3). 
DISCUSSION
In this study, we showed that SDC1 expression is increased 
in cervical cancer and that most of the SDC1 accumulates in 
the cytoplasm of cancer cells. The finding that high grade tu­
mors show decreased expression of SDC1 is consistent with a 
Fig. 1. Representative syndecan-1 immunohistochemical staining in (A) normal cervical epithelium and cervical cancer, (B) negative, (C) weak 
positive, (D) strong positive (×200).Yu Im Kim, et al.
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previous report [15].
Silencing SDC1 expression causes reduced focal adhesion 
plaque formation and enhanced cell spreading and motility 
on collagen I substrates [16]. Considering the fact that spread­
ing and motility of cancer cells are highly related to invasion 
and distant metastasis, SDC1 positive tumors might have a 
more favorable biological behavior. This possible benefit of 
SDC1 may explain the findings that SDC1 expression is more 
co  mmon in low grade tumors and that patients with strong 
SDC1 expression have more favorable outcome in survival 
analysis.
We also showed that increased amounts of SDC1 is confined 
to the cytoplasm of tumor cells. Normal membranous distri  bu­
tion of SDC1 vanished in the neoplastic cells. Due to trans  po­
si  tion of SDC1 from the cytoplasmic membrane to cytoplasm, 
the cells lose effective SDC1 on their surfaces. Considering 
the function of SDC1, these cells might lose con  nection to the 
extracellular matrix and move more freely than normal cells. 
In    creased mobility of the cells can contribute to invasion and 
metastasis. Alteration of SDC1 distribution may be caused by 
de  gradation of the glycosaminoglycan chains, or expression 
of a mutated core protein that cannot undergo glycanation 
[17]. 
In one report, an inverse correlation between the expression 
of SDC1 in the tumor and lymph node metastasis was sugge­
sted [18]. However, they failed to show statistical significance, 
as we did.
In other malignancies, such as endometrial cancers [19] and 
invasive ductal breast carcinomas [20], SDC1 expression is 
reported to be associated with better prognosis. However cer­
tain malignancies, such as gallbladder cancer [14] and pros­
tate cancer [21], it has been reported to have shorter survival 
time with positive SDC1 expression. This contradictory effect 
of SDC1 might be due to the difference of the site of origin 
that the tumors have come from.
SDC1 can be detached from the cytoplasmic membrane and 
become soluble form. The soluble SDC1 is associated with 
shorter survival in chronic lymphocytic leukemia [22] and lung 
cancer [23]. SDC1 expression of the bone marrow environ­
ment is associated with shorter event­free survival of multiple 
myeloma [24]. Adverse effect of SDC1 expression in tumor 
stroma has also been reported in oral carcinomas [25] and 
pancreatic cancer [26].
Decreased expression of SDC1 can be ascribed to increased 
degradation of the protein in cancer cells without any change 
in the gene expression. As a mechanism of decreased SDC1, 
decreased biosynthesis of the protein is suggested in gastric 
cancer [27]. Sometimes changes in copy number of a gene re­
sult in alterations in gene expression. To find a cause of SDC1 
expression change, we screened the copy number of SDC1 
and found no alteration in its copy number. It seems that al­
teration of SDC1 expression is caused by changes other than 
copy number alteration. The mechanism of SDC1 expression 
in malignant cell is not known to date.
We found two reports claiming that SDC1 expression did 
not predict survival [28,29]. In those articles, authors scored 
immunoreactivity of SDC1 on the surface of cells. SDC1 can 
be found on the surface of normal epithelial cells, and cervi­
cal cancer cells may retain SDC1 expression on the surface. 
Table 1. The relationship between syndecan-1 (SDC1) expression and 
pathological parameters of cervical cancers
Pathological 
parameters No. (%)
SDC1 expression
p-value Strong 
positive
Weak positive 
or negative
Age
    ≥50 61 (50.4) 56 (46.3) 5 (4.1) 0.025*
    <50 60 (49.6) 45 (37.2) 15 (12.4)
Histological type
    SCC 97 (80.2) 87 (71.9) 10 (8.3) 0.001*
    Adeno+adenoS 24 (19.8) 14 (11.6) 10 (8.3)
Grade
    I-II 113 (93.4) 97 (80.2) 16 (13.2) 0.025*
    III 8 (6.6) 4 (3.3) 4 (3.3)
Stage
    I 69 (57.0) 56 (46.3) 13 (10.7) 0.588
    II-IV 52 (43.0) 45 (37.2) 7 (5.8)
Recurrence
    Yes 17 (14.0) 13 (10.7) 4 (3.3) 0.480
    No 104 (86.0) 88 (72.7) 16 (13.2)
Lymph node metastasis
    Yes 32 (28.3) 26 (23.0) 6 (5.3) 0.947
    No 81 (71.7) 68 (60.2) 13 (11.5)
SCC, squamous cell carcinoma; Adeno, adenocarcinoma; AdenoS, 
adenosquamous carcinoma.
*Statistically significant.
Table 2. Prognostic factors for disease-specific survival selected by 
Cox’s multivariate proportional hazard regression model
Hazard 
ratio
95% Confidence 
interval
Cox’s test 
p-value
Tumor grade (III) 5.51 1.85-16.43 0.002*
Histological type 1.43 0.83-2.47 0.20
Age ( ≥50) 1.95 0.78-4.91 0.15
Syndecan-1
 (strong positive)
0.34 0.13-0.87 0.03*
*Statistically significant.Syndecan-1 expression in cervical cancers
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Because we focused on abnormal location of SDC1 in tumor 
cells, we scored cytoplasmic expression of SDC1. With this 
scoring scheme, we found that strong SDC1 expression was 
associated with better survival. This explains the difference of 
our results and previous reports.
In conclusion, we showed intense SDC1 expression is asso­
ciated with better prognosis in cervical cancer. Tumor grade 
and histological type is also related to the SDC1 expression. 
The alteration of SDC1 expression in cervical cancer is not 
caused by copy number changes of SDC1 in the tumor.
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Fig. 2. Flurorescence in situ hybridization (FISH) of syndecan-1 (SDC1). (A) Location of homemade SDC1 probe was confirmed on metaphase 
spread of normal peripheral mononuclear cells. (B) There is no copy number alteration of SDC1 in interphase FISH of cervical cancer tissue (Red 
spot, SDC1; Green spot, chromosome 2 centromere).
Fig. 3. Survival analysis between groups showing different amount of syndecan-1 expression. Weak positive group and negative group have 
similar survival curve. Statistically significant difference was noted between strong positive group and other groups (p=0.0219).Yu Im Kim, et al.
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